Apolipoprotein A-I in the human monocyte/macrophage cell lines: the expression and the putative functions


This review outlines the modern concepts concerning functions of high density lipoproteins and their major protein component apolipoprotein А-I (ApoA-l) in the development of atherosclerotic lesions. The discussion of anti-inflammatory ApoA-l activity as well as the regulation of apoA-l gene expression by proinflammatory cytokine TNFa is underlined. There are original data about the expression of apoA-l gene in human monocyte-macrophage lineages. Stimulation of human monocytes and macrophages by TNFa leads to an activation of apoA-l expression in those cells in contrast to the effect of TNFa on human hepatocytes and enterocytes, where there is a downregulation of apoA-l expression. The putative functions of ApoA-l synthesized by macrophages are discussed, in particular the stabilization effect of ApoA-l on ABCA1 transporter which possesses the antiatherogenic properties.

S V Orlov

Email: serge@iem.sp.ru

D A Mogilenko

A P Perevozchikov

Email: app@iem.sp.ru

  1. Виленская Е.Г., Лапиков И.А. Изучение экспрессии гена аполипопротеина А-I в эмбрионе мыши // Мол. мед. 2009. № 1. С. 35-39.
  2. Воробьёв Е.В., Перевозчиков А.П. Исследование экспрессии гена аполипопротеина А-I на ранних стадиях эмбриогенеза человека методом гибридизации in situ // Онтогенез. 1992. Т. 23. № 5. С. 469-478.
  3. Климов A.H., Никульчева Н.Г. Обмен липидов и липопротеидов и его нарушения: Рук-во для врачей. СПб.: Питер, 1999. 500 с.
  4. Перевозчиков А.П. Стеролы и их транспорт в развитии животных // Онтогенез. 2009. Т. 39. №3. С. 165-189.
  5. Ansell B.J., Navab М., Watson K.E. et al. Antiinflammatory properties of HDL // Rev. Endocr. Metab. Disord. 2004. Vol. 5. Ss 4. P. 351-358.
  6. Banka C.L. High density lipoprotein and lipoprotein oxidation // Curr. Opin. Lipidol. 1996. Vol. 7. № 3. P. 139-142.
  7. Barter P.J., Rye K.A. Molecular mechanisms of reverse cholesterol transport // Curr. Opin. Lipidol. 1996. Vol. 7. № 2. P. 82-87.
  8. Barter P.J., Nicholls S., Rye K. A. et al. Antiinflammatory properties of HDL // Circ. Res. 2004. Vol. 95. № 8. P. 764-772.
  9. Baroukh N., Lopez C.E., Saleh M.C. et al. Expression and secretion of human apolipoprotein A-l in the heart // FEBS Lett. 2004. Vol. 557. P. 39-44.10.
  10. Beers A., Haas M.J., Wong N.C.W., Mooradian A. Inhibition of Apolipoprotein AI Gene Expression by Tumor Necrosis Factor a : Roles for MEK/ERK and JNK Signaling.// Biochemistry. 2006. Vol. 45. № 7. P. 2408-2413.
  11. Boyle J.J. Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture // Curr. Vase. Pharmacol. 2005. Vol. 3. № 1. P. 63-68.
  12. Bresnihan B., Gogarty M., FitzGerald O. et al. Apolipoprotein A-l infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? // Arthritis Res. Ther. 2004. Vol. 6. № 6. P. R563-566.
  13. Burger D., Dayer J. M. High-density lipoprotein-associated apolipoprotein А-I: the missing link between infection and chronic inflammation? // Autoimmunol. Rev. 2002.Vol. 1. № 1-2. P. 111-117.
  14. Cabana V.G., Lukens J.R., Rice K.S. et al. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease // J. Lipid. Res. 1996. Vol. 37. 12. P. 2662-2674.
  15. Chan J., Nakabayashi H., Wong N.C. HNF-4 increases activity of the rat Apo Al gene // Nucleic. Acids. Res. 1993. Vol. 21. P. 1205-1211.
  16. Claudel T., Sturm E., Duez H. et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-l transcription via a negative FXR response element // J. Clin. Invest. 2002. Vol. 109. P. 961-971.
  17. Cockerill G.W., Rye K.A., Gamble J.R. et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules // Arterioscler. Thromb. Vase. Biol. 1995. Vol. 15. № 11. P. 1987-1994.
  18. Connelly M.A., Williams D.L. SR-BI and cholesterol uptake into steroidogenic cells//Trends Endocrinol. Metab. 2003. Vol. 14. № 10. P. 467-472.
  19. Dean M., Hamon Y., Chimini G. The human ATP-binding cassette (ABC) transporter superfamily // J. Lipid Res. 2001. Vol. 42. P. 1007-1014.
  20. Delerive P., Galardi C.M., Bisi J.E. et al. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription // Mol. Endocrinol. 2004. Vol. 18. P. 2378-2387.
  21. Diederich W., Orsó E., Drobnik W., Schmitz G. Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42 //Atherosclerosis. 2001. Vol. 159. № 2. P. 313-324.
  22. Doherty N.S., Littman B.H., Reilly K. et al. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis // Electrophoresis. 1998. Vol. 19. № 2. P. 355-363.
  23. Duan H., Li Z., Mazzone T. Tumor necrosis factor-α modulates monocyte/macrophage apoprotein E gene expression // J. Clin. Invest. 1995. Vol. 96. P. 915-922.
  24. Eggerman T.L., Hoeg J.M., Meng M.S. et al. Differential tissue-specific expression of human apoA-I and apoAII // J. Lipid. Res. 1991. Vol. 32. № 5. P. 821-828.
  25. Epand R.M., Stafford A., Leon B. et al. HDL and apolipoprotein А-I protect erythrocytes against the generation of procoagulant activity II Arterioscler. Thromb. 1994. Vol. 14. № 11. P. 1775-1783.
  26. Esteve E., Ricart W., Fernández-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism /7 Clin. Nutr. 2005. Vol. 24. № 1. P. 16-31.
  27. Furlaneto C.J., Ribeiro F.P., Hatanaka E. et al. Apolipoproteins А-I and A-II downregulate neutrophil functions // Lipids. 2002. Vol. 37. № 9. P. 925-928.
  28. Ge R., Rhee M., Malik S., Karathanasis S.K. Transcriptional repression of apolipoprotein AI gene expression by orphan receptor ARP-1 II J. Biol. Chem. 1994. Vol. 269. P. 13185-13192.
  29. Gentili C., Tutolo G., Pianezzi A. et al. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression // Matrix. Biol. 2005. Vol. 24. P. 35-44.
  30. Gerbod-Giannone M.C., Li Y., Holleboom A. et al. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells // Proc. Natl. Acad. Sei. USA. 2006. Vol. 103. №9. P. 3112-3117.
  31. Glomset J. A. The plasma lecithins:сholesterol acyltransferase reaction // J. Lipid. Res. 1968. Vol. 9. №2. P. 155-167.
  32. Gough P.J., Gordon S. The role of scavenger receptors in the innate immune system // Microbes Infect. 2000. Vol. 2. №3. P. 305-311.
  33. Haas M.J., Horani M., Mrcyoud A. et al. // Biochim. Biophys. Acta. 2003. Vol. 1623. № 2-3. P. 120-128.
  34. Hamon Y., Chambenoit O., Chimini G. ABCA1 and the engulfment of apoptotic cells // Biochim. Biophys. Acta. 2002. Vol. 1585. P. 64-71.
  35. Han K.H., Han K.O., Green S.R., Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function // J. Lipid. Res. 1999. Vol. 40. №6. P. 1053-1063.
  36. Hansson G.K. Immune mechanisms in atherosclerosis // Arterioscler. Thromb. Vase. Biol. 2001. Vol. 21. P. 1876-1890.
  37. Harnish D.C., Malik S., Sotirios K., Karathanasis S.K. Activation of apolipoprotein AI gene transcription by the liver-enriched factor HNF-3 // J. Biol. Chem. 1994. Vol. 269. № 45. P. 28220-28226.
  38. Higuchi K., Law S.W., Hoeg J.M. et al. Tissue-specific expression of apolipoprotein A-l (ApoA-I) is regulated by the 5’-fianking region of the human ApoA-І gene // J. Biol. Chem. 1988. Vol. 263. №34. P. 18530-18536.
  39. Huuskonen J., Vishnu M., Chau P. et al. Liver X receptor inhibits the synthesis and secretion of apolipoprotein Al by human liver-derived cells // Biochemistry. 2006. Vol. 45. № 50. P. 15068-15074.
  40. Hyka N., Dayer J.M., Modoux C. et al. Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes // Blood. 2001. Vol. 97. № 8. P. 2381-2389.
  41. Ishiguro H., Yoshida H., Major A.S. et al. Retrovirus-mediated expression of apolipoprotein А-I in the macrophage protects against atherosclerosis in vivo // J. Biol. Chem. 2001. Vol. 276. P. 36742-36748.
  42. Ivanov G.S., Kater J.M., Jha S.H. et al. Sp and GATA factors are critical for Apolipoprotein AI downstream enhancer activity in human HepG2 cells // Gene. 2003. Vol. 323. P. 31-42.
  43. Khovidhunkit W., Memon R.A., Feingold K.R., Grunfeld С. Infection and inflammation-induced proatherogenic changes of lipoproteins // J. Infect. Dis. 2000. Vol. 181. Suppl. 3. P. S462-472.
  44. Kilbourne E.J., Widom R., Harnish D.C. et al. Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription // J. Biol. Chem. 1995. Vol. 270. P. 7004-7010.
  45. Kim K.D., Lim H.Y., Lee H.G. et al. Apolipoprotein А-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation // Biochent. Biophys. Res. Commun. 2005. Vol. 338. № 2. P. 1126-1136.
  46. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport // Circ. Res. 2005. Vol. 96. № 12. P. 1221-1232.
  47. Libby P. Inflammation in atherosclerosis // Nature. 2002. Vol. 420. P. 868-874.
  48. Linsel-Nitschke P., Tall A.R. HDL as a target in the treatment of atheroscleroticcardiovascular disease // Nat. Rev. Drug. Discov. 2005. Vol. 4. № 3. P. 193- 205.
  49. Maciejko J.J., Holmes D.R., Kottke B.A. et al. Apolipoprotein А-I as a marker of angiographically assessed coronary-artery disease // N. Engl. J. Med. 1983. Vol. 309. № 7. P. 385-389.
  50. Major A.S., Dove D.E., Ishiguro H. et al. Increased cholesterol efflux in apolipoprotein AI (ApoAl)-pro-ducing macrophages as a mechanism for reduced atherosclerosis in ApoAI(-/-) mice // Arterioscler. Thromb. Vase. Biol. 2001. Vol. 21. P. 1790-1795.
  51. Martin G., Schoonjans K., Lefebvre A.M. et al. Coordinateregulation of the expression of the fatty acidt ransport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators // J. Biol. Chem. 1997. Vol. 272. P. 28210-28217.
  52. Mogilenko D.A., Dizhe E.B., Shavva V.S. et al. Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein А-I gene expression in HepG2 cells // Biochemistry. 2009. Vol. 48. № 50. P. 11950- 11960.
  53. Mogilenko D.A., Trulioff A.S., Ivanov A.S. et al. TNFalpha activates endogenous expression of human apolipoprotein А-I in monocytes and macrophages: role of NFkappaB, MAP-kinases and nuclear receptors LXRs and PPARalpha /7 J. Biol. Chem. 2010. (submitted for publication)
  54. Murphy A.J., Woollard K.J., Hoang A. et al. High density lipoprotein reduces the human monocyte inflammatory response // Arterioscler. Thromb. Vase. Biol. 2008* Vol. 2. P. 2071-2077.
  55. Navab M., Hama S.Y., Cooke C.J. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1 //J. Lipid. Res. 2000. Vol. 41. P. 1481-1494.
  56. Navarro M.A., Carpintero R., Acin S. et al. Immuneregulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation // Cytokine. 2005. Vol. 31. № 1. P. 52-63.
  57. Pisciotta L., Hamilton-Craig I., Tarugi P. et al. Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders // Atherosclerosis. 2004. Vol. 172. № 2. P. 309-320.
  58. Plump A., Scott C., Breslow J. Human apolipoprotein А-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse // Proc. Natl. Acad. Sci. USA. 1994. Vol. 91. № 20. P. 9607-9611.
  59. Porto A., Palumbo R., Pieroni M., Bianchi M. E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein // FASEB J. 2006. Vol. 20. № 14 P. 2565-2566.
  60. Reddy S. A.G., Huang J.H., Liao W.S.-L. Phosphatidylinositol 3-kinase as a mediator of TNF-Induced NF-{kappa} B activation // J. Immunol. 2000. Vol. 164. P. 1355-1363.
  61. Richardson B., Palgunachari M.N., Anantharamaiah G.M. et al. Human placental tissue expresses a novel 22.7 kDa apolipoprotein A-I-Iike protein // Biochemistry. 1996. Vol. 35. P. 7580-7585.
  62. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport // Curr. Opin. Lipidol. 2010. Vol. 21. № 3. P. 229-238.
  63. Rottman J.N., Widom R.L., Nadal-Ginard B. et al. A retinoic acid-responsive element in the apolipoprotein AI gene distinguishes between two different retinoic acid response pathways // Mol. Cell. Biol. 1991. Vol. 11. P. 3814-3820.
  64. Rubin E., Krauss R., Spangler E., Verstuyft J., Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI // Nature. 1991. Vol. 353. № 6341. P 265-267.
  65. Sastry K.N., Seedorf U., Karathanasis S.K. Different cis-acting DNA elements control expression of the human apolipoprotein AI gene in different cell types // Mol. Cell. Biol. 1988. Vol. 8. № 2. P. 605-614.
  66. Schaefer E.J., Lamon-Fava S., Ordovas J.M. et al. Factors associated with low' and elevated plasma high density lipoprotein cholesterol and apolipoprotein А-I levels in the Framingham Offspring Study // J. Lipid. Res. 1994. Vol. 35. № 5. P. 871-882.
  67. Schmitz G., Buechler C. ABCA1: regulation, trafficking and association with heteromeric proteins // Ann. Med. 2002. Vol. 34. № 5. P. 334-347.
  68. Seimon T., Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis // J. Lipid. Res. 2009. Vol. 50. P. S382-S387.
  69. Seetharam D., Mineo C., Gormley A.K. et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I // Circ. Res. 2006. Vol. 98. № L P. 63-72.
  70. Song H., Saito K., Fujigaki S. et al. iLl-beta and TNF-alpha suppress apolipoprotein (apo) E secretion and apo А-I expression in HepG2 cells // Cytokine. 1998. Vol. 10. № 4. P. 275-280.
  71. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu С. et al. Human serum Paraoxonase/Arylesterase’s retained hydrophobic N-tenninal leader sequence associates with HDLs by binding phospholipids: apolipoprotein А-I stabilizes activity // Arterioscler. Thromb. Vase. Biol. 1999. Vol. 19. № 9. P. 2214-2225.
  72. Srivastava R.A., Srivastava N. High density lipoprotein, apolipoprotein A-l, and coronary artery disease // Mol. Cell. Biochem. 2000. Vol. 209. № 1-2. P. 131-144.
  73. Su Y.R., Ishiguro H., Major A.S. et al. Macrophage apolipoprotein А-I expression protects against atherosclerosis in ApoE-deficient mice and up-regulates ABC transporters // Mol. Ther. 2003. Vol. 8. P. 576-583.
  74. Tangirala R.K., Tsukamoto K., Chun S.H. et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein А-I in mice // Circulation. 1999. Vol. 100. № 17. P. 1816-1822.
  75. Thorp E., Tabas I. Mechanisms and consequences of efferocytosis in advanced atherosclerosis // J. Leukoc. Biol. 2009. Vol. 86. Ne 5. P. 1089-1 095.
  76. Wang X., Rader D.J. Molecular regulation of macrophage reverse cholesterol transport // Cun. Opin. Cardiol. 2007. Vol. 22. № 4. P. 368-372.
  77. Widom R.L., Rhee M., Karathanasis S.K. Repression by ARP-1 sensitizes apolipoprotein AI gene responsiveness to RXR alpha and retinoic acid // Mol. Cell. Biol. 1992. Vol. 12. P. 3380-3389.
  78. Yvan-Charvet L., Pagler T.A., Seimon T.A. et al. ABCA1 and ABCGl Protect Against Oxidative Stress Induced Macrophage Apoptosis During Efferocytosis // Circ. Res. 2010. Vol. 106. APUB.
  79. Zhang Y.Z., Zanotti I., Reilly M.P. et al. Overexpression of apolipoprotein А-I promotes reverse transport of cholesterol from macrophages to feces in vivo // Circulation. 2003. Vol. 108. № 6. P. 661-663.
  80. Zheng X.L., Matsubara S., Diao C. et al. Activation of apolipoprotein Al gene expression by protein kinase A and kinase С through transcription factor. Sp. 1 // J. Biol. Chem. 2000. Vol. 275. P. 31747-31754.


Abstract - 43




  • There are currently no refbacks.

Copyright (c) 2010 Orlov S.V., Mogilenko D.A., Perevozchikov A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies